0Suppliers
14Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

LakeShore Biopharma Co., Ltd (LSBCF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships
2Distinct source URLs
3High confidence
0.681Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

LakeShore Biopharma Co., Ltd Suppliers

No suppliers on recordLakeShore Biopharma Co., Ltd does not appear to disclose named supplier relationships in its verified regulatory filings, or upstream suppliers have not yet been identified. Our system processes new filings continuously.

LakeShore Biopharma Co., Ltd Customers

TickerNameConfidenceEvidence
SNYNF Sanofi 72% 023 was primarily from a net loss for the fiscal year of RMB145.5 million adjusted for certain non-cash items, which included deferred income taxes RMB1.1 million, depreciation of RMB29.7 million, am…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from LSBCF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from LSBCF graph: 023 was primarily from a net lo…
ACCORDINGLY-LAKESHORE-GROUP ACCORDINGLY-LAKESHORE-GROUP 62% NOTE 12 – WARRANTS As of March 31, 2024, Lakeshore Group has 10,750,000 public warrants and 6,000,000 private warrants. Lakeshore Group accounts for its outstanding warrants in accordance with ASC 81…
AS-LAKESHORE-GROUP AS-LAKESHORE-GROUP 62% FV is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level FV hier…
ASU-LAKESHORE-GROUP ASU-LAKESHORE-GROUP 62% ly evaluating the provisions of this ASU. Lakeshore Group does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on Lake…
CHINA-LAKESHORE-GROUP CHINA-LAKESHORE-GROUP 62% revention (“CDCs”) in China. Lakeshore Group does not have a concentration of its revenue and accounts receivable with specific customers. As of March 31, 2024 and 2023, there was no customer which a…
CUSTOMERS-LAKESHORE-GROUP CUSTOMERS-LAKESHORE-GROUP 62% rant outstanding immediately prior had ceased to be a warrant with respect to Summit Public Shares and was assumed by Lakeshore Biopharma and converted into a Lakeshore Biopharma Warrant entitling th…
IF-LAKESHORE-GROUP IF-LAKESHORE-GROUP 62% sh flows expected to result from the use of the asset group plus net proceeds expected from disposition of the asset group, if any, is less than the carrying value of the asset group. If Lakeshore Gr…
INVENTORIES-NET-LAKESHORE-GROUP INVENTORIES-NET-LAKESHORE-GROUP 62% NOTE 4 – ACCOUNTS RECEIVABLE, NET Accounts receivable, net are as follows: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Trade receivables 487,418,616 473,515,321 $ 66,739,298 Allowance for expect…
LONG-LIVED-ASSETS-LAKESHORE-GROUP LONG-LIVED-ASSETS-LAKESHORE-GROUP 62% ed separately are measured at initial cost. The cost of intangible assets acquired in a business combination is the FV at the date of acquisition. The useful lives of intangible assets are assessed t…
SUMMIT-LAKESHORE-GROUP SUMMIT-LAKESHORE-GROUP 62% NOTE 12 – WARRANTS As of March 31, 2024, Lakeshore Group has 10,750,000 public warrants and 6,000,000 private warrants. Lakeshore Group accounts for its outstanding warrants in accordance with ASC 81…
THEREFORE-LAKESHORE-GROUP THEREFORE-LAKESHORE-GROUP 62% or services. Step 1: Identify the contract with the customer; Step 2: Identify the performance obligations in the contract; Step 3: Determine the transaction price; Step 4: Allocate the transaction p…
WARRANTS-LAKESHORE-GROUP WARRANTS-LAKESHORE-GROUP 62% the same manner as the property, plant and equipment are depreciated. Warrants Lakeshore Group accounts for warrants as either equity-method or liability-method instruments based on an assessment of …
WHEN-LAKESHORE-GROUP WHEN-LAKESHORE-GROUP 62% NOTE 7 – PREPAID EXPENSES AND OTHER CURRENT ASSETS, NET Prepaid expenses and other current asset, net consist of the following: As of March 31, 2023 2024 2024 (RMB) (RMB) (US$) Deposits (1) 4,339,791…

LakeShore Biopharma Co., Ltd Debt Obligations

InstrumentDescriptionConfidenceEvidence
LSBCF-DEBT-10802 Warrants outstanding: 100 90% xbrl warrant detail from xbrl 2025-03-31.
LSBCF-DEBT Debt stack $62.3M 90% Market cache reports total debt of $62.3M.

LakeShore Biopharma Co., Ltd Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for LakeShore Biopharma Co., Ltd.

LakeShore Biopharma Co., Ltd Ownership

HolderNameConfidenceEvidence
LSBCF-OWNER-BARCLAYS-PLC BARCLAYS PLC 90% 13F overlay lists BARCLAYS PLC as top holder; 1 tracked holders.

LakeShore Biopharma Co., Ltd Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ADAG Adagene Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
GRDX GridAI Technologies Corp. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
BMRN BioMarin Pharmaceutical Inc. 100.00 2
🔐
LSBCF
Unlock LSBCF Supply Chain Data
Verified relationships include:
SNYNFSanofiCustomer72%
SNYNFSanofiCustomer72%
+13 more relationships locked
Subscribe, View plans →